Product Description
Benzonatate is used to relieve coughs due to colds or influenza (flu). It is not to be used for chronic cough that occurs with smoking, asthma, or emphysema or when there is an unusually large amount of mucus or phlegm with the cough. Benzonatate relieves cough by acting directly on the lungs and the breathing passages. It may also act on the cough center in the brain. (Sourced from: https://www.mayoclinic.org/drugs-supplements/benzonatate-oral-route/precautions/drg-20062223?p=1)
Mechanisms of Action: Voltage-Gated Sodium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Egypt | India | Korea | Mexico | Taiwan | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|